Printed from the IBC Life Sciences Web site on December 11, 2013 1:20 PM ET.
Page location: http://www.ibclifesciences.com/CellTherapy/overview.xml
Engineering Designer Immunity to Leukemias Through Chimeric Antigen Receptor T Cells Induces Durable and Complete Clinical Responses
Bruce Levine, Ph.D.
Barbara and Edward Netter Associate Professor in Cancer Gene Therapy
University of Pennsylvania
Commercialization of an Autologous Cell Therapy Product
Knut Niss, Ph.D.
Senior Technical Project Leader, Global Biopharm Operations
Universal Donors as the Backbone of Therapeutic Therapies: Development of Commercial Cell Therapy Products
John McMannis, Ph.D.
Executive Vice President of Manufacturing
Managing Market Requirements, Potency and Scalable Considerations for Allogeneic Manufacturing
Robert Deans, Ph.D.
Executive Vice President, Regenerative Medicine
Challenges and Future Directions for Commercial Scale Patient-Specific Production
Brian Hampson, M.S.
Senior Director, Engineering and Innovation
Join our priority contact list and receive the latest event news.
Special Discounted Hotel Rate Available Until September 27, 2013. To book your room, call 1-800-228-9290 or 301-897-9400 and mention that you are an IBC attendee at this event.
IBC's Cell Therapy Bioprocessing conference has already built a reputation of providing a first-rate faculty of participants, who collectively share perspectives and lessons learned from detailed case studies to help you overcome the challenges, develop the strategies and implement the technologies to propel this field towards commercial sustainability. In 2013, we will continue to serve as a bridge to help companies move their cell therapies from laboratory to commercial scale because this event is committed to establishing cell therapies as a viable and profitable industry.
"The best commercial manufacturing conference in cell therapy to date. Period!" - Lee Buckler, Cell Therapy Group
"The IBC Cell Therapy conference is an excellent collection of the brightest minds in the cell therapy industry discussing the most critical subjects facing cell therapy today." - Nathan Smith, Mesoblast
"Practical relevant information for companies regardless of clinical phase you are in. Knowledgeable and engaging presenters with great lessons learned and best practices filled the program." - Ellen Colket, Lonza
"The first conference that combined classical bioprocessing tech and industry with academic and clinical fields." - Ricardo Baptista, University of Toronto
"This must-attend forum explores the industry's greatest challenges to develop and manufacture cellular therapies and offers real-world solutions to help you achieve commercial success." - Peter Zandstra, University of Toronto
"This was one of the top bioprocessing meetings last year, and 2012 should be even better. With approval trials advancing in the cell therapy space, requirements for scalable manufacturing positioned to meet COGS and reimbursement targets has growing importance. This creates market opportunity from the bioprocessing industry, whose entry has been long been needed." - Robert J. Deans, Athersys, Inc.
"This year's Cell Therapy Bioprocessing event expands on the foundation that was created at last year's event. It addresses all aspects of cell therapy development, from process issues and product characterization to regulatory concerns. From novices to experienced scientists in this area, there will be something that attendees can learn from the event, and should not be missed!" - Ron Fedechko, Pfizer Inc.
"Cellular bioprocessing is essential to enable scalable and cost effective cell based products to advance into the clinical arena. Anyone from academia or industry interested in an update on state of the art in cellular bioprocessing should consider attending this year's IBC event. A great venue to network and meet key thought leaders in the field." - Jeffrey Karp, Harvard Medical School and Harvard-MIT Division of Health Sciences and Technology
"In order for the entire field to progress, it is imperative that those of us in regenerative medicine participate in discussion forums such as the IBC Cell Therapy conferences in order to move beyond the basic science, and share knowledge (both what works and what does not) that would enable successful clinical commercialization." - Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, BioLife Solutions, Inc.